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Dr Peter Boyle,
Session 2A: Lung Cancer Radiotherapy - trial recruitment
Dr Matthew Hatton, Suresh 5enan
Weston Park Hospital, Whitham Rd, Sheffield, UK
Radiotherapy research in the UK - trials and tribulations
Recruitment of lung cancer patients into radiotherapy trials is proving difficult in the UK and
internationally. The session aims to provide a brief overview of recent trials, the current UK lung trial
portfolio and future study ideas The NCRI lung site specific group has identified palliative radiotherapy
in lung cancer as a research priority and also sees research opportunities around the development of
stereo-tactic radiotherapy in the UK. In addition recruitment issues will be discussed which have led to
the early closure of a number of recent trials.
The two European PCI studies recently reached accrual target and have now been reported. Following
on from these studies a trial proposal looking at the role of palliative thoracic radiotherapy in extensive
stage small cell lung cancer is in an advance stage of preparation. The role, dose and fractionation of
palliative thoracic radiotherapy in NSCLC is less clear now that chemotherapy is in more widespread use
for patients with advanced and metastatic disease.
The UK has yet to develop stereo-tactic radiotherapy treatment for lung cancer. A number of centres
have been investing in the radiotherapy hardware needed and are planning to start treatment programs
over the next few years. It is planned to discuss the use of shared protocols for stereo-tactic
radiotherapy to aid the development of a UK service while maximising the opportunity for research and
participation in multi-centre and international studies.
Session 3: Lung Cancer: The NCR! Strategic Plan
Prof Mike Richards
Director of NCRI, St Thomas' Hospital, Adamson Centre for Mental Health, London, UK
Session 4: Molecular Profiling of Lung Cancer
Dr Tim Crook
Professor Gabriella Sozzi, Francesca Andriani, Davide Conte,L. Mariani, U.Pastorino, Luca
Roz
Cytogenetics and MolecularCytogeneticsUnit, Department of Experimental Oncology, Fondazione
IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy
Circulating DNA as diagnostic marker for early detection of lung cancer
Introduction: Early diagnosis of lung cancer represents one of the most promising strategies to reduce
the high mortality rates from this disease that constitutes the leading cause of cancer death worldwide.
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The identification of free circulating DNA in the blood of lung cancer patients has provided an excellent
opportunity to devise non-invasive tests for early detection, but the search for tumour specific changes
has been hampered by the low levels of DNA and by the lack of markers with sufficient sensitivity and
specificity. An alternative approach is represented by the evaluation of the total amount of free
circulating DNA as a marker of disease.
We have performed three different studies to evaluate whether the level of free plasma DNA could
discriminate between lung cancer patients and healthy individuals and whether a screening test based
on this biomarker is feasible in the context of screening programs. Initially, DNA quantification and
analysis of microsatellite alterations were performed in a consecutive series of 84 patients with non-
small cell lung cancer, who were also studied during follow-up, and 43 healthy controls. In patients, the
mean values of plasma DNA concentration were higher than in controls even considering stage Ia
patients. Furthermore variations in DNA level and in microsatellite changes correlated with the clinical
status of 38 patients monitored during follow-up. To measure with greater accuracy the amount of free
circulating DNA, a quantification approach based on real-time quantitative polymerase chain reaction
(qPCR) was developed, using as a target the human telomerase reverse transcriptase gene (hTERT).
The performance of the test was evaluated in 100 non-small-cell lung cancer patients and 100 age-,
sex-, and smoking-matched controls and median concentration of circulating plasma DNA in patients
was found to be almost eight times the value detected in controls (24.3 vs. 3.1 ngjml). The area under
the ROC curve was 0.94 (95% CI, 0.907 to 0.973) indicating that this could represent a new, non-
invasive approach for early detection of lung cancer. Finally we investigated the impact of long-term
storage of both plasma samples and purified plasma DNA on the reproducibility of the qPCR
quantification assay. The analysis was performed on samples from a subset of 34 lung cancer patients
and 28 matched control subjects selected from 200 subjects of the previous case-control study and
from 117 cancer-free smokers enrolled in a lung cancer screening program. DNA levels were found to
decline substantially between different assessments at an average rate of approximately 30% per year
highlighting the need for careful planning of retrospective studies in large screening trials.
Given the high sensitivity and specificity of the qPCR test, that proved to be independent from tumor
size, we decided to test the value of plasma DNA quantification in combination with spiral CT for early
lung cancerdetection.
Purpose: We assessed the screening performance and prognostic value of plasma DNA levels in a
cohort of heavy smokers monitored with annual spiral-CTfor 5 years.
Methods: Plasma DNA levels were determined through real-time quantitative PCR amplification of
human telomerase reverse transcriptase (hTERT) gene in 1035 volunteers of a screening trial at
baseline and at time of lung cancer diagnosis. Screening performance of the assay was calculated
through the area under the receiver-operating characteristic curve (AUC-ROC). Kaplan-Meier analyses
were computed for association with prognosis.
Results and Conclusions: Median baseline concentration of plasma DNA was similar in CT-detected lung
cancers and cancer-free controls (AUC-ROC 0.496, p= 0.9330), while it was slightly higher in cancers at
the time of diagnosis (AUC-ROC 0.607, p= 0.0369). Plasma DNA was higher in tumors detected at
baseline (AUC-ROC 0.80, P<O.OOOl) and in Stage II-IV tumors detected during the first 2 years of
screening (AUC-ROC 0.87, P<O.OOOl). A longitudinal study of plasma DNA levels showed increased
values approaching to lung cancer diagnosis (p=0.0010). Higher plasma DNA was significantly
associated with poorer 5-year survival (p=0.0066).
This study showed an overall limited discriminatory power of plasma DNA levels for identification of
lung cancer patients in a CT-screening setting, with better performance in particular subsets. However,
changes in plasma DNA levels during follow-up were indicative of lung cancer onset and thus helpful for
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disease onset monitoring. Importantly, an elevated concentration of circulating plasma DNA at surgery
was associated with a shorter 5-years survival in resected patients suggesting that plasma DNA are
prognostic of those CT-detected tumors that really have an impact on the outcome of the patients.
Conversely lower levels of plasma DNA at surgery might represent a marker of slow-growing lung
cancers detected by spiral CT.
Professor Elisabeth Brambilla , A. Van den Broeck, S. Lantuejoul, C. Brambilla, S. Gazzeri
Centre Hospital Universityof Grenoble, France
The Prognostic Value of Histone-Code in Non Small Cell Lung Carcinoma
Background: Epigenetic modifications refer to a number of molecular mechanisms that regulate gene
expression without changing the DNA sequence which include: 1) alteration of methylation status of
DNA within CpG islands, with hypermethylation of CpG islands promoters of tumor suppressor genes
leading to their silencing; 2) covalent modification of histone tails; 3) a chromatin remodelling and 4)
micro RNAs (1, 2). Epignetic modifications of histones namely acetylation and methylation of lysine
residues in the tails of nucleosomal core histones play crucial role in chromatine packaging, gene
expression, nuclear architecture and genomic stability (1-6). Overall, histone hypoacetylation and
hypermethylation is characteristic of DNA sequence that are methylated and repressed in normal cells.
Trimethylation of H4 lysine 20 (H4K20) is a mark of constitutive heterochromatin in normal quiescent
cells, gene silencing and aging. Acetylation and methylation of lysine residues in N terminal tails of
histone H4 affect high order chromatin structure, transcriptional regulation of genes and DNA repair,
suggesting a role in carcinogenesis.
In cancer cells, hypermethylation of promoters CpG islands of transcriptionally repressed tumor
suppressor genes are associated with a particular combination of histone marks like deacetylation of
histones H3 and H4, loss of histone H3 lysine K4 (H3K4) trimethylation, and gain of H3K9 and H3K27
trimethylation. In human cancer and multistage carcinogenesis models, cancer cell exhibit a loss of
acetylated K16 and of trimethylated K20 residues of histone H4 associated with repetitive DNA
sequences (pericentromeric or telomeric).
Epigenetic modifications of histones seem to have strong importance in the development of certain
tumor types. During prostate carcinogenesis histone patterns were predictors of clinical outcome
independentof tumor stage, pre-operative PSA levels, and capsule invasion (7).
In lymphoma, colon and breast cancer and hepatocarcinogenesis induced by carcinogens in rats H4
lysine 20 trimethylation was associated with aberrant expression of histone methyl transferases (Suv39,
Suv40-h1 or h2).
In lung cancer an array of histone H2 and H3 modification in acetylation and trimethylation, as detected
by immunohistochemistry on paraffin sections in surgical resectable NSCLC and SCLC allowed
distinction of 7 groups of patients with differential prognosis (p=O,OOOl for disease free survival and
overall survival) (8).
Results: We demonstrated the impact of histone code changes in the lung cancer progression and
prognosis. In 157 NSCLC including 50 squamous cell carcinoma (SCC) and 107 adenocarcinoma (ADC)
(including 80 stage I) we performed an immunohistochemical analysis of acetylated H4K5, H4K8,
H4K12, and H4K16, and trimethylated H4K20 (H4K20me3). Global modifications of histone H4
acetylation included an overrepresentation of acetylated H4K5 and H4K8 as compared to their low
levels in normal bronchial and alveolar epithelial cells; in contrast, with a decrease of acetylated H4K12
and H4K16 as compared to their high level in normal lung epithelial cells. Distribution of these H4
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acetylated pattern was shifted according to histological type except for H4K16 acetylated (H4K16ac).
High levels of H4K5ac and H4K8-ac. were more frequent in SCC, whereas low level of H4K12ac were
predominant in ADC (p<O,OOl). No additional significant correlation of H4K5/K8/K12/K16 acetylations
was found with c1inico-pathological parameters.
Loss of trimethylation of H4K20, as compared with normal lung epithelial cells was observed in 70 % of
NSCLC, more frequently in SCC than in ADC (p<O,OOOl) with a strong inverse relation between H4K8ac
and H4K20me3 (H4K20 trimethylated) (p=O,0008).
The lack of correlation of loss of H4K20me3 with stage in SCC suggesting an early process, we sought
an involvement of H4K20me3 loss during the stepwise morphological changes of preinvasive bronchial
lesion (hyperplasia, metaplasia, dysplasia, and CIS) using immunohistochemical analysis on frozen
sections. We noticed a partial loss of H4K20me3 as soon as basal hyperplasia, an increased loss of
H4K20me3 with progressive grades towards complete negativity in most CIS. We concluded that
H4K20me3 loss is an early process leading to SCC lung cancer development from the basal bronchial
stem cell.
In contrast with SCC, H4K20me3 loss was related to stage in ADC being less frequent in stage I than in
stage II-IV (p<O,Ol) allowing recognition of two stage I populations with or without H4K20me3 loss.
Loss or low level of H4K20m3 on a total set of 80 stage I ADC was associated with shorter overall
cancer related survival in Kaplan Meier analysis (p=O,007). The median survival time of patients with
low score H4K20 was 114 months ±2,8 and was not reached for patients with high H4K20me3 level.
The 5-year survival rate was 30 % in low or loss H4K20me3 versus 5 % for patients without loss.
In order to uncover the possible mechanisms of reduced H4K20me3 we performed an RT-PCR analysis
on microdissected tumor tissue to evaluate the level of expression of histone methyltransferases (HMT)
SUV420h1 and h2 known to catalyse H4K20 trimethylation. We found that tumors with a low level of
H4K20me3 disclosed a decrease of Suv4-20h2 (p=O,019) but not of Suv4-20h1 (p=O,37), suggesting
that Suv4-20h2 might playa role in the deregulation of H4K20 trimethylation in lung cancer.
Discussion: The post-operative management of stage I NSCLC is still a matter of debate specially
regarding the use of adjuvant chemotherapy in stage IB which 5-years survival rate in surgically treated
patients does not exceed 55 %. Survival attempts have been made to subcategorize stage I patients for
risk of death or recurrence (9-11), but different sets of genes differentially expressed the same cancer
type raised the question of whether these data provide sufficiently robust and reproducible pieces of
information. These gene profiles may provide prognostic information but do not predict efficiency of
therapy. In this context it is tempting to suggest that disregulation of H4K20 me3 and more widely of
histone modification in lung cancer contribute to cancer initiation and/or progression. It has been
recently shown that decreased level of H4K20 me3 affect telomere lengths in cells deficient for HMT
Suv4-20h2 leading to escape to DNA repair and replicative senescence (12). We have shown that
telomere shortening is characteristic of early preinvasive bronchial lesions(13).
This study offers a rational for evaluation of sensitivity to usual drugs (cisplatin) and compounds,
targeting histone modifications in NSCLC as several histone deacetylated inhibitors have been
developed.
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DNA Methylation Surrogate Biomarkers for Diagnosis of NSCLC.
Lung cancer is the number one cause of cancer related deaths world-wide. DNA methylation
abnormalities comprise a common phenomenon in human lung cancer and thus it is suggested that
DNA methylation based biomarkers may assist in diagnosis, prognosis and patient stratification towards
individualised therapeutic regimes. Although a lot of data has already been produced, the spectrum of
DNA methylation markers with the high potential in clinical use is not yet clear. We still lack large
retrospective and prospective studies with high statistical power that are required to provide adequate
sensitivity and specificity. Within our methylation biomarker discovery programme, we have
collaborated with industrial partners employing high throughput platforms such as microarrays and
Mass Array®. Selected targets based on that data and integrated information from the literature
included p16, RAR alpha, MGMT, TMEFF2, RASSF1, MAGEA3 and others. Technical validation was
performed by Pyrosequencing in an independent set 48 NSCLCs and their counterpart normal tissues.
We were able to read up to 12 CpGs in a semi-quantitative manner and thus calculate the methylation
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index (MtI) for each gene. GAS, p57, MAGEA3 and LINE-1 were heavily methylated in normal tissue
while their MtI was reduced in tumour tissue. In contrast, p16, RARB, MGMT and CYGB presented very
low basal levels of methylation in normal tissue while they were frequently methylated in tumour tissue.
It is of note that p16 methylation correlated with concordant RARB methylation (p=0.004) and MGMT
methylation (p=0.009) suggesting a methylator phenotype in a subgroup of the samples. There was
also a trend to associate high methylation index with nodal metastasis (Mann-Whitney, p=0.1). It is of
note that most of the potential methylation markers for NSCLC were also highly ranked in our
collaborative oral cancer biomarker programme. We have currently selected a number of such positive
genes and developed qMSP (real-time PCR) assays with high sensitivity and specificity. We use these
assays to screen one retrospective collection of cases (n=120) and matched controls (n=120) from the
Liverpool Lung Project study. We have also initiated a prospective collection of individuals with impaired
lung function through a network of general practices aiming to combine DNA methylation biomarkers in
sputum with cytology and spiral CT screening. Our findings support the idea that quantitative methods
able to screen long stretches of the gene promoters are required to select CpGs with higher sensitivity
and specificity for future diagnostic purposes. Targeted qMSP assays can then be applied to clinical
specimens under good clinical laboratory practice (GCLP) guidelines in order to provide reliable
diagnostic results.
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NELSON - CT Screening trial
Background: Early lung cancer detection with X-ray was unable to reduce lung cancer mortality. Low
dose spiral CT screening cohort studies have demonstrated that lung cancer can be detected at an early
stage in a high percentage. Unknown is whether spiral CT screening will lead to a lung cancer mortality
reduction and if lung cancer screening will be cost-effective. Given the high rate of screen positive test
results (median value 20%) and the low positive predictive value (median 8%) improvement of the
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diagnostic performance of the screen regimen is needed. These questions will be addressed in the
randomised Dutch-Belgian-Danish lung cancer screening trial (NELSON) of 20,000 participants.
Methods: 30,531 male and female high-risk current and former smokers between 50-75 years of age
have been selected based on their smoking history (at least 16 cigarettes a day for at least 26 years or
at least 11 cigarettes a day for at least 31 years) from a random sample of 613,248 subjects of the
Dutch-Belgian population of whom 15,996 signed the informed consent and were randomised between
LDCT screening in year 1, 2 and 4 and a control arm without screening. Computer software for semi-
automated volumetry (LungCare®, Siemens Medical Solutions) was integrated in the screen regimen.
CT scans are performed with 16-detector multi-slice Spiral CT scanners and Siemens Lungcare®
workstations and software for volumetric analyses in all 4 screening sites. The Lungcare radiological
data are automatically uploaded in the NELSON Management System (NMS). Outcome of the screening
test was based on the largest nodule size and highest growth category found. Only one repeat scan per
year was allowed to limit radiation exposure and costs.
Results and Conclusions: In the Netherlands and Belgium, 15,822 subjects have been randomized
(1:1) and have undergone baseline and 2nd round sceening one year later. Of them, 83% was male and
17% female, 56% current smoker and 44% former smoker. The majority of current (n=1558) and
former (n=1355) smokers had a smoking history of 30-39 PY. Of the former smokers, 62% had quit <
6 yrs and 36% between 6-10 yrs. In total 13,081 nodules have been detected at baseline. Of them,
66% were benign or < 50 rnrn" and needed no further evaluation, 20% was indeterminate and 4% was
larger than 500 mrrr' and required further work-up and evaluation. Data on the diagnostic test
performance of this novel screen regimen in which volumetry was integrated, detection rates, disease
stage, volume doubling times and natural history of individual nodules after 2 years of follow-up will be
presented at the meeting.
Professor Denise R. Aberle, MD
Professor of Radiology and Bioengineering, David Geffen School of Medicine at UCLA, Department of
Radiological Sciences
Lung Cancer Screening with CT
Lung cancer is the leading cause of cancer death in the United States. In 2007, it is estimated that
160,390 lung cancer deaths will occur in the US, representing 29% of all cancer deaths (1). Non-small
cell lung cancer (NSCLC), which accounts for 75-80% of all lung cancers, is typically diagnosed when
disease is locally advanced or there are systemic metastases (2), explaining the dismal overall five-year
survival of 15% (3). In contrast, the five-year survival of individuals with surgically resected, early
stage NSCLC approaches 75% (3,4). These differences have fueled the impetus to find a screening
test that can detect NSCLC in its early preclinical stages, when surgical resection is most likely to
prolong life and potentially reduce lung cancer mortality.
Although earlier, small randomized controlled trials of lung cancer screening using chest radiography
and sputum cytology failed to show reduced lung cancer mortality, computed tomography (CT) is a
much more sensitive test for detecting small lung nodules and several observational studies have
generated considerable enthusiasm for CT as a potential contemporary screening tool for lung cancer
(5-12). The results of these studies have provided many insights. The prevalence of indeterminate
lung nodules varies Widely depending on both the spatial quality of the scan and the lower threshold of
size for calling an opacity a "nodule." Most individuals at risk who are screened with CT (>90%) will
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not have lung cancer. CT detects more lung cancers than does chest radiography (5,6); a high
percentage of these cancers will be early stage when diagnosed. The survival of CT screen-detected
lung cancers is increased relative to historical controls-which are typically symptom-detected (11).
While these observations are encouraging, the demonstration of increased survival is itself insufficient
evidence of screening benefit. When applied to screening, survival statistics are subject to the biases
of lead time, length, and overdiagnosis. Ultimately, increased survival can occur absent a meaningful
benefit from screening, defined as a decrease in lung cancer-specific mortality. Beyond benefit,
screening trials must show that the benefits of screening outweigh the risks-across all individuals
screened, not only those with lung cancer. Some preliminary studies using modeling have questioned
whether CT screening will provide a mortality benefit and suggest that the risks resulting from over-
utilization of surgery alone are significant (12). Finally, chest CT provides a window to the evaluation
of multiple organs and conditions. The collective consequences of all screening observations, the
diagnostic follow-up associated with these imaging findings, the complications of downstream tests,
and the potential to treat patients who neither require nor will benefit from treatments must be
weighed against the unbiased measure of mortality benefit.
The results of the ongoing large-scale randomized controlled trials, such as the National Cancer
Institute-sponsored NLST (National Lung Screening Trial) and the NELSON trial ongoing in the
Netherlands, are designed to address the benefit of CT screening by comparing differences in lung
cancer-specific mortality between individuals at risk of lung cancer who undergo CT screening and
those who do not (13,14,15). The NLST has 90% power to addressa difference of 20% in lung cancer
specific mortality between two arms that have received annual screening with either CT or chest
radiographs (CXR). Beyond lung cancer-specific mortality, the NLST will measure all cause mortality,
the performance of CT and CXR in lung cancer detection, and medical resource utilization in
participants with positive screens as well as subsets of individuals with negative screens and individuals
with clinically significant findings unrelated to lung cancer. In subsets of participants accrued by sites
affiliated with the American College of Radiology Imaging Network (ACRIN), quality of life related to
screening and to positive screening results is being measured, a cost effective analysis has been
designed, and biospecimens have been collected for validating biomarkers of early lung cancer that
prove promising in other preliminary research (16).
The NLST is the collective effort of many researchers from several medical disciplines and more than 33
institutions (15). The imaging equipment, which included at a minimum 4-detector row helical CT
scanners, periodic calibration testing, and standardized acquisition parameters for both CT and CXR
were overseen by a multi-institutional physics committee (17). Radiologists trial-wide developed
diagnostic pathways to use as quldelines for positive screening results. Rigorous practices were
established at the outset to ensure that all trial data and adverse events would be reviewed bi-annually
by an independent data and safety monitoring board. Moreover, the accuracy of the primary
endpoint-lung cancer mortality-as well as deaths potentially related to screening are being assessed
by an independent endpoint verification committee of physicians who will review source medical
records of participants blinded to death certificates. The final results of the trial are anticipated some
time after 2010.
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Current Status of CT Sceening
Recently concerns have emerged that spiral CT is ineffective in reducing lung cancer-related mortality
due to some combination of overdiagnosis and overtreatment (1). Since lung cancer is the world's most
lethal cancer, it is essential to precisely understand the data regarding lung cancer early detection
efficacy so that we may progress in reducing the mortality burden of this disease.
Refined manual approaches to diagnostic work up allow additional diagnostic imaging work ups to be
performed in about 12% of baseline screenees. Further diagnostic work-up is required only in 10%(2).
Of that 1% of subjects with evidence of nodule growth undergo needle aspiration and 90% of those
work ups being positive. This indicates that the true false positive call and surgical intervention are
improving the efficiency of delivering screening services. Sensitivity of lung cancer screening with spiral
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CT is reported to be 97% (3). The frequency of interval detected cancers has greatly decreased from
30-50% of cases with chest X-ray detection to a low single digit number with current spiral CT
results(4-5). As a result the 35% 5-year survival reported by Marcus et al with chest X-ray screening
has been supplanted with the over 80% 10-year survival being reported by Heneschke and co-workers
from their multi-institutional experience(4-5). Recent modeling analyses of the results from early spiral
CT lung cancer screening reports suggest a mortality reduction benefit of 23%.
Promising results are emerging from the Japanese surgical experience in using more limited surgical
results for small volume primary lung cancer. The American College of Surgery is sponsoring a
randomized comparison of standard lobectomy with a less aggressive surgical approach. This specific
management information is complementary to anticipated randomized early detection trial data in
allowlnq us to understand the current and future benefit of lung cancer screening.
Session 10: Targeted therapies - a learning curve
Dr Paul Bunn
University of Colorado Cancer Center, Denver, USA
Outcomes for most patients with stage 4 non-small cell lung cancer (NSCLC) remain poor with a median
survival of one year or less. There is considerable enthusiasm for a more individualized approach in
which an optimal treatment regimen is selected based on the biologic molecular features of a patient's
tumor. In the simplest form the selection feature could be histology and there is evidence that NSCLC
patients with an adenocarcinoma or large cell carcinoma histology have a superior outcome with a
pemetrexed/clsplatln combination while squamous carcinomas have a superior outcome with a
gemcitabine/cisplatin combination compared to pemetrexed/cisplatin.
Inhibitors of the EGFR pathway were shown to have activity in refractory NSCLC patients although
response rates in unselected patients were low. Nonetheless, single agent erlotinib produced a superior
survival compared to best supportive care in NSCLC patients who had failed initial chemotherapy.
Randomized trials of gefitinib or erlotinib given concurrently with chemotherapy failed to show benefit,
likely because of negative interactions and lack of selection. On the other hand, combinations of
cetuximab with chemotherapy appear to provide survival benefit but only in patients selected for EGFR
positivity. It does not appear to matter whether the cetuximab treatments are given sequentially or
concurrently with chemotherapy. FISH selection was for superior for survival benefit compared with IHC
testing. Single agent EGFR TKIs or EGFR TKIs alternating with chemotherapy are being compared to
chemotherapy in untreated NSCLC patients selected by clinical and molecular features.
The outcomes with antiangiogenic agents are far less clear. Bevacizumab prolonged progression free
survival in two trials comparing platinum doublets alone or with bevacizumab. However, only the ECOG
trial with carboplatin and paclitaxel plus bevacuzimab at 15 mg/kg dose showed superior survival.
There are no known selection factors to select the patients most likely to benefit although patients with
squamous histology and those with hemoptysis should not receive bevacizumab because of increased
toxicity. It is not clear whether toxicity is increased in patients with brain metastases and those on
anticoagulants. Two randomized trials comparing platinum doublets alone to platinum doublets with
small molecule TKI inhibitors of the VEGF receptor, including sorafanib and AZD2171 showed no benefit
from the combination and toxicity was increased, especially in squamous carcinomas and in males.
Thus, major questions remain on the use of antiangiogenic antibodies and TKIs. Other novel agents
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have shown promise in early trials including anti-IGF-IR antibodies, c-rnet inhibitors and irreversible
pan-ErbB inhibitors.
Session 11: Emerging clinical trials
Professor Nick Thatcher
Christie Hospital NHS Trust, Manchester, UK
Anti - Angiogenetic Approaches to Lung Cancer Treatment
The Folkman hypothesis [Folkman N Engl J MED 1971] proposed that for solid tumours to grow beyond
2-3mm_ required vascularisation to overcome the diffusion limits of oxygen and nutrients, further more
tumour angiogenesis factor was thought to be the mediator of the neovascularisation. Many factors
cause tumours to produce Vascular Endothelial Growth Factor (VEGF) including hypoxia, oncogenes
and a variety of other growth factors. The VEGF in turn leads to tumour angiogenesis followed by
enhanced survival, proliferation, migration, and metastatic propensity of the tumour.
VEGF function can be targeted by the anti-VEGF monoclonal antibody (bevacizumab), anti-VEGF
receptor antibodies (IMC-1121) and decoy soluble receptors that bind VEGF (VEGF Trap technology).
Bevacizumab(Bev) is the only anti VEGF that has shown an increase survival when combined with a
standard chemotherapy regimen, carboplatin, paclitaxel in a selected group of patients e.g. non
squamous, little or no previous haemoptysis, no eNS metastases etc. [Sandler et ai, N Eng J Med
2006]. A supportive placebo three arm trial using gemcitabine/cisplatin reached its primary endpoint of
improved progression free survival with Bev at either a 7.5 or 15 mgs/kg dose[Manegold et al Proc
ASCO 2007].Bev in combination with standard adjuvant chemotherapy(CT) is now being examined in
randomised phaseIII trials.
The interaction between VEGF inhibitors and epidermal growth factor receptor (EGFR) inhibitors was
investigated in a 3 arm phase II trial .A similar if not better survival with a bev. + erlotinib (BE)
combination over standard single agent, 2nd line CT was reported [Herbst et al J Clin Oncol 2007]. The
BE combination is being investigated as an alternative to standard 1st line CT with Bev (B02057ltrial)
and as maintenance treatment following non-progression after 1st line chemotherapy (ATLAS trial). In
the 2nd line setting EB is being compared to E alone (BETA trial).
There are a large variety of anti-VEGF TKIs which can be given orally, many involVing multiple targets
including EGFR, c-kit etc. Some of these trials with the oral TKls have included patients with squamous
cell carcinoma and on occasions CNS metastases in an attempt to broaden the patient population
beyond the patients eligible for Bev. However, side effects such as skin rash, hand foot syndrome,
diarrhoea and unusual effects such as QT change on ECG and hoarseness have been noted.
Furthermore, some trials with 1st line paclitaxel carboplatin have been stopped this year by
Independent Data Monitoring Committees on the basis of lack of likely efficacy and/or toxicity,
particularly in the squamous cell population (AZD 2171 BR24 trial, sorafenib ESCAPE trial) with
implications for future trial design.
Other trials are investigating the value of the multi-targeted TKls in the 2nd/3rd line setting e.g.
sunitinib with erlotinib against erlotinib alone, and as maintenance therapy versus placebo followlnq
objective response or stable disease following standard 1st line CT. There are several trials
investigating vandetanib in 2nd/3rd line some recently completing accrual he There are also a number of
other drugs which affect VEGF production e.g. HIF which may be useful antiangiogenic targets.
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A large number of issues have yet to be resolved concerning the generalisation of the CT backbone, the
appropriate patient population, the most clinically relevant endpoint, interactions with other treatments
e.g. radiotherapy and as yet the lack of a predictive biomarker. Logically given the number of worthy
candidates it would be reasonable to develop multi -arm (3 or greater) randomised phase II trials to
identify the most promising newcomer for subsequent Phase III trials.
Dr Rafael Rosell
Catalan Institute of Oncology, Hospital Germans Trias i PUjol, Ctra Canyet, 08916 Badalona, Spain
New small molecule inhibitors
The shift away from the use of non-specific cytotoxic agents in cancer therapy to more specific,
molecularly targeted aqents' (eg, bevacizumab, erlotinib, gefitinib, cetuximab) can lead to the
development of so-called "Phase 0" trials, integrating biomarkers to identify the right target
population" Paradoxically, large phase III trials of molecularly targeted agents have demonstrated a
rather limited beneflt'", highlighting the need to identify the proper molecularly defined target
population.
There are several ongoing clinical trials of small molecule inhibitors of DNA damage response and
related signaling pathways'. ATM and ATR are central to cellular responses to double strand breaks",
When activated, ATM and ATR phosphorylate a multitude of proteins, initiating a cascade that induces
cell-cycle arrest and facilitating DNA repatr" 10. An inhibitor of ATM kinase activity, KU55933, is currently
in preclinical developmenf, and attenuators of checkpoint signaling are also being tested: for example,
XL844 (EXEL-9844), a small molecule inhibitor of CHK1 and CHK27• Post-translational modifications of
proteins include the addition of nucleotides, such as poly(ADP-ribosyl)ation. Poly(ADP-ribosyl)ation is
critical for a wide range of processes, including DNA repair, regulation of chromosome structure,
transcriptional regulation, mitosis and apoptosls". Inhibitors of poly(ADP-ribose) polymerase (PARP)
have been tested in inherited breast and ovarian cancers with BRCA1 or BRCA2 dysfunction (BRCA1
and BRCA2 mutated cells defective in homologous repair). The recombination-defective tumor cells are
100-1000-fold more sensitive to PARP inhibitors than are the heterozygote or the Wild-type cell lines,
indicating their potential to be exploited as specific treatment of BRCA1- or BRCA2-defective tumors'<
13. PARP inhibitors induce single-strand breaks that can result in double strand breaks as a consequence
of stalled replication forks. Such lesions would normally be repaired by homologous recombination, but
this is abrogated in BRCA1- or BRCA2-deficient cancer cells. The inhibition of PARP leads to the
persistence of these DNA leslons", In addition to its role in the repair of stalled replication forks, PARP
activity is also required for the actions of checkpoint protein with forkhead-associated and ring finger
domains (CHFR)ll. CHFR deficiency causes cells to fail to delay chromosome condensation and nuclear
envelope breakdown in response to paclitaxel or nocodazole'", Video micrographic assays indicate that
the point at which CHFR acts is in late G2 or antephase". A PARP inhibitor, KU-005894812, compromised
the ability of Ptk1 cells to delay nuclear envelope breakdown in response to microtubule poisons.
Instead, the majority of the treated cells continued into mltosls'", CHFR is downregulated in lung
cancer", and we have found CHFR methylated in circulating DNA of 94 (31.3%) of 300 metastatic non-
small-cell lung cancer patients. CHFR and RNF8 are human RING E3 ubiquitin ligases whose forkhead
domains are typically modules found in DNA repair and checkpoint proteins. RNF8jUBC13 complexes go
to sites of DNA damage through their forkhead domain and initiate the synthesis of K63 polyubiquitin
chains on chromatin that recruits the BRCA1 complex" 10. CHFR can also catalyze the formation of K63-
linked polyubiquitin chains with UBC13-MMS217• Based on these observations, translational studies in
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NSCLC patients with low BRCA1 mRNA levels, with or without CHFR methylation, could be useful for
combining platinum-based chemotherapy with PARP inhibitors.
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Prof Egbert Smit
Dept of Pulmonary Diseases, Vrije Universiteit VUMC, Amsterdam The Netherlands
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Prof Ian M Adcock
Airways Disease Section, National Heart & Lung Institute, Imperial College London, Dovehouse Street,
London SW3 6LY, UK
Epigenetic regulation of inflammation in COPO and lung cancer
Recent evidence has re-established the link between cancer promotion and/or exacerbated and
inflammation. Indeed, chronic inflammation orchestrates a tumour-supporting microenvironment that
is an indispensable participant in the neoplastic process. Paracrine mediators such as, cytokines,
growth factors, proteases, etc produced by activated innate immune cells, and bacterial cell wall
products are able to stimulate tumour growth and progression. Furthermore, the soluble mediators
produced by cancer cells recruit and activate inflammatory cells, which further stimulate tumour
progression leading to a feed-forward amplification of the drive towards disease.
Cigarette smoking causes lung cancer, with approximately 10 to 15% of active smokersdeveloping lung
cancer. Lung cancer risk is associated with chronic obstructive pulmonary disease (COPD) although it is
not clear if this association is attributable to a shared exposure to cigarette smoke, to shared genetic
susceptibility factors, and/or to facilitation of tumour initiation and promotion by inflammation.
Importantly, lung cancer mortality in non-smokers has been associated with emphysema and
emphysema/chronic bronchitis rather than smoking
COPD is the fourth commonest cause of death worldwide and involves a chronic inflammatory process
affecting peripheral airways and lung parenchyma. The pattern of pulmonary inflammation in COPD is
specific and increases in intensity with the disease severity. The inflammation in COPD appears to be
an amplification of the normal inflammatory response to inhaled noxious agents primarily cigarette
smoke and does not resolve when smoking stops. The underlying mechanism for this exaggerated
inflammatory response is not yet fully understood.
There are a number of frequently detected mutations associated with lung cancer such as EGFR, K-ras
and p53 mutations, however, it is becoming clear that epigenetic modifications may be associated with
both the inflammatory response to cigarette smoke and to lung cancer growth and progression.
Changes in the DNA methylation status of tumour suppressor genes have been reported in lung cancer
and recent evidence has highlighted the ability of inflammatory stimuli to acutely regulate DNA
methylation patterns in inflammatory genes. Increased histone acetylation has been linked to
increased inflammatory gene expression particularly in response to cigarette smoking. Exposure to
cigarette smoke can cause a reduction in the expression and activity of specific histone deacetylases
such as HDAC2 and Sirtuin 1 which has been linked to the enhanced inflammation observed in COPD.
Furthermore, HDAC inhibitors have recently been associated with enhanced tumour metastasis.
Whether epigenetic changes observed in patients with lung cancer and COPD may be linked will be
discussed.
Session 14: GWAS and Risk Assessment Models
Or Paolo Boffetta
International Agencyfor Research on Cancer, Lyon, France
Contribution of genome-wide association studies to risk models for lung cancer
While a heritable component for lung cancer has long been recognized, progress in identifying
susceptibility genes has been slow. To identify genetic factors that modify disease risk and would be
incorporated in risk models, we conducted a genome-wide association study of lung cancer. The initial
phase consisted of an analysis of 317,139 SNP in 1,989 lung cancer cases and 2,625 matched controls
from six Central European countries. We identified a locus in chromosome region 15q25 that was
strongly associated with lung cancer (p=9x10-10). This locus was replicated in five separate studies
comprising an additional 2,518 cases and 4,752 controls (p=5x10-20 overall), and it was found to
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account potentially for 14% of lung cancer cases in European populations. The association region
contains several genes, including three that encode for nicotine acetylcholine receptors (CHRNA5,
CHRNA3, and CHRNB4). We have extended the genome-wide analysis by including two further studies
comprising an additional 750 cases and 800 controls. After pooling genome-wide and replication phase
results, two additional variants were strongly associated with lung cancer, suggesting new susceptibility
loci.
Prof Stephen Duffy
Mathematicsand Statistics, Wolfson Institute of Preventive Medicine, London, UK
Exploitation of the Liverpool Lung Project Risk Model in Selecting Populations for
Intervention
There are a number of models for the prediction of individual risk of lung cancer'", The Liverpool Lung
Project (LLP) model, estimated using the LLP case-control study of 579 cases and 1157 age- and sex-
matched controls, with support from Cancer Research UK, is relatively simple, being based on a limited
number of risk factors: smoking duration, family history of lung cancer, personal history of other
malignancies, personal history of pneumonia and exposure to asbestos', The odds ratios of relative risk
estimates are combined with incidence rates of lung cancer by age and gender to give absolute five-
year risks of lung cancer.
The model is already in use in a number of general practices in Liverpool. The GP enters the age and
sex of the patient, along with the risk factors listed above and the programme returns a five-year
probability of being diagnosed with lung cancer. Examples of absolute risk for a combination of factors
will be discussed. Ten-fold internal cross-validation has been carried out, suggesting that the prediction
is accurate. The average area under the ten ROC curves was 74%. Work is continuing on the model,
including external validation and software development to cope with missing data and render the model
more flexible and user-friendly.
In this presentation, we demonstrate how such an individual risk model can be used to select subjects
for intervention, for example a screening programme. If a given resource is available, the ROC curve
can be used to define a cut-off which will include the number of high-risk subjects which the resource
can afford. This reasoning was instrumental the UK's National Cancer Research Institute to investigate
the feasibility of a UKTrial of low-dose CT screening for lung cancer.
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Early Lung Cancer Detection Program Using Risk Prediction Model
While sophisticated technologies such as low dose spiral CT, autofluorescence bronchoscopy and optical
coherence tomography are available to detect early lung cancer down to the micron range, applying
these technologies to screening of lung cancer among smokers in the general population is unlikely to
be practical or cost-effective because of variation in lung cancer risks. Spiral CT is very sensitive but the
false-positive rate is relatively high resulting in unnecessary or potentially harmful downstream
investigations and/or treatment. Bronchoscopy under conscious sedation can detect early lung cancer in
the central airways not visible by spiral CT and allow cytologic, histologic or genomic diagnosis of lung
cancer. However, it is comparatively more expensive and time consuming than spiral CT. In the
context of a health care delivery system, these technologies need be used in a selective fashion.
A lung cancer prediction model was developed using social - demograhic factors and clinical data from
participants in the US NCI Prostate, Lung, Colorectal and Ovarian cancer screening study. The model
was validated in 2422 former and current smokers enrolled in several NCI sponsored chemoprevention
trials in Vancouver. The area under the receiver operating curve (AUC) was 0.74. The incremental
benefit of adding other biomarkers such as lung function or sputum atypia by image analysis was
evaluated. The AUC was found to improve the AUC to 0.78 with either biomarker. A novel approach
was used to discover blood biomarkers that may enhance the accuracy of the prediction model further.
The proteomic profiles of pulmonary venous blood draining from the tumor vascular bed was compared
with that in systemic blood and also between venous blood before and after surgical resection of the
tumor. Several promising biomarkers such as CTAP III/NAP-2 were found. The biomarkers were
validated in two population based cohorts - venous blood from volunteer smokers with and without
lung cancer prior to enrolment onto a chemoprevention trial and smokers who participated in the
NHLBI Lung Health Study. Addition of the blood biomarkers was found to improve the AUC of the
prediction model further to 0.84. Our findings suggest that using a multivariate prediction model, we
can rapidly and inexpensively screen former and current smokers for more intensive studies with spiral
CT and autofluorescence bronchoscopy. A Pan-Canadian Early Lung cancer Detection Study is being set
up to test the use of this lung cancer risk prediction model to enrol current and former smokers for
spiral CT and autofluorescence bronchoscopy. Using short-term outcomes from this study including
detection rates and costs, the results will be compared with other on-going randomized studies such as
the NLST and NELSON trial in the US and EU to provide an informed decision for the implementation of
lung cancer screening in Canada.
Supported by the Terry Fox Research Institute, Canadian Partnership Against Cancer, BCCA MDS-Rix
Endowment Fund, Vancouver Hospital Foundation, NIH/NCI & CIHR
Session 15: Molecular Epidemiology - risk and assessment
Dr Margaret Spitz, Xifeng Wu, Qingyi Wei, Christopher I. Amos, Carol Etzel
Department of Epidemiology,The University of Texas M.D. Anderson CancerCenter, Texas USA
Risk Prediction for Lung Cancer: An integrative Epidemiology Approach
Reliable risk prediction tools for estimating the probability of lung cancer have substantial public health
implications and value in early detection and clinical decision making. There are an estimated 45 million
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current smokers in the United States and 49 million former smokers. The challenge is to identify that
subset of ever smokers at higher risk for developing lung cancer. Such high-risk individuals could
undergo a program of screening surveillance that might not be appropriate for a lower risk population,
receive the most intensive smoking cessation interventions, and may consider chemoprevention
interventions. Further, risk prediction tools could be incorporated into the design of smaller, more
powerful, and "smarter" prevention trials. Those few models that have been developed use sex, age,
smoking phenotype, and in one instance, a limited occupational exposure assessment (1,2).
We have constructed and internally validated clinical tools for lung cancer risk prediction for current,
former and never smokers, based on epidemiologic and clinical data derived from an ongoing lung
cancer case control study. We used data from 1851 non Hispanic white lung cancer patients and 2001
matched controls (3). Variables included were environmental tobacco smoke (for never and former
smokers only), family cancer history, dust exposure, prior respiratory disease, and smoking history
variables (pack years for current smokers and age stopped smoking for former smokers). All variables
have strong biologically plausible etiologic roles, and are relatively easy to ascertain through patient
interview. The validated concordance statistics for the former and current smoker models were modest
(0.63, and 0.58, respectively), although consistent with those from other risk prediction models. Since
these models were based on white populations, they need to be modified for use in other ethnic
groups.
Since the precision of this model was modest, we have also estimated the degree of improvement
obtainable by adding markers of DNA repair capacity (host cell reactivation and mutagen sensitivity
assays) that have been shown to be independent risk factors for lung cancer (4,5). Our data suggest
that addition of biomarker assays significantly improved the sensitivity of the expanded models over the
baseline (epidemiologic and clinical data) model. These assays, however, are time-consuming, require
some level of technical expertise, are therefore not applicable for Widespread population-based
implementation, but are feasible in a controlled academic setting. The next step in model refinement is
to include genotyping data that are inexpensive, accurate and amenable to high-throughput analysis.
The availability of whole genome scan data adds substantial promise to this approach (6).
The unifying premise of Integrative epidemiology is that the same genes that are implicated in cancer
risk, may also be involved in a person's propensity to carcinogenic exposure and/or prediction of patient
outcome. We are therefore taking the same approach to constructing risk prediction models for
outcome and response to therapy.
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Session 16A: Mesothelioma: clinical overview and discussion of possible future trials?
Dr Martin Muers
Leeds ChestClinic, Martin Wing, Leeds General Infirmary, Great George Street, Leeds LSI 3EX, UK
Introduction: Mesothelioma has a unique epidemiology which is changing and this affects possible
treatments and has to direct research. The parameters are that it is almost always incurable. There is
no RCT evidence that any treatment is curative. Long term survivors exist but are very rare, less than
1% at five years, and examples exist of this after all types of treatments including multi-modality, lone
chemotherapy or even ASC (active supportive care) as is seen in lung cancer. Importantly, the median
age is currently 75 in western Europe and is predicted to rise to 80 by 2020 and 85 by 20205 while the
epidemic is still at its height. Currently 35% of patients at presentation are performance status 3-4 and
this proportion is likely to rise together with worsening co-morbidity.
Pathogenesis: Asbestos is a carcinogen. There has been considerable debate as to whether the virus
SV40 is relevant to pathogenesis, but it would appear from the most recent research, that this is
unlikely in at least the vast majority of cases.
Screening and early detection: Mesothelioma at the present time does not reach the criteria required
before commencing a screening trial because no curative treatment or treatment likely to appreciably
alter prognosis currently exists. Currently, in Europe, the heightened risk is spread very thinly
throughout a huge population of relatively mildly exposed individuals particularly in the construction
industry and although these individuals have a much higher risk of disease than the unexposed
population, nevertheless each individual's risk is relatively low. To be effective, it is likely that
screening would have to continue well into the 7th decade.
Methods: The possibilities are imaging and tumour markers. Very early mesothelioma is not visible on
CT, MRI or PET scanning. For logistic reasons, high quality CT scanning is the likeliest candidate but
given that, it is in practice very difficult to disentangle early mesothelioma from benign asbestos related
disease and benign non-asbestos related disease and a corrolarly of any screening programme would
be a major requirement for (frequently negative) thoracoscopy. There has been great interest recently
in the possibility that either mesothelin or osteopontin might be tumour markers suitable not only for
patient management but also for screening in the exposed population. In practice, the data available at
present suggests that there is a major problem with both markers in respect of false positives, i.e.
persons who have raised marker values but who do not have the disease. Further studies are in
progress.
Likewise, data is awaited on the prospective use of these markers as an adjunct to management, in
particular, evidence of response or relapse and a requirement for second or third line treatment.
Attempted cure: There have been repeated reports particularly from the US suggesting improved
prognosis after triple therapy (nee-adjuvant chemotherapy, surgery by pleuropneumonectomy and
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followed by hemi-thorax radiation in curative doses). Currently, there is one RCT in progress. This is
the MARS (UK) trial which is currently undergoing a feasibility study to assess whether patients will
accept randomisation after neo-adjuvant chemotherapy and restaging with a negative mediastinoscopy
to active supportive care or surgery and radiotherapy treatments.
Improving prognosis: Usually in surgical fields there has been a suggestion that reducing tumour bulk
(as for ovarian cancer) may improve the prognosis. The favoured technique is open or VATS
pleurectomy. There is a single randomised controlled trial in progress (MESO-VATS UK), which is
recruiting slowly but may provide valuable evidence on this point.
Chemotherapy: Borderline improvements of 2-3 months in the median survival have been reported in
selected patients in two RCTs which compared Pemetrex plus Cisplatin versus Cisplatin alone
(Vogelzang, p less than 0.05) and Raltitrexed plus Cisplatin versus Cisplatin alone (VanMeerbeck pless
than 0.048). The MS01 study (Muers 2008) shows a suggestion of an improvement in survival and
borderline improvement in time to progression comparing Vinorelbine as a single agent versus active
supportive care (p less than 0.52). Probably all three drugs and perhaps others such as Gemcitabine
do have some activity in this disease and there is no evidence that anyone agent or combination is
better or worse than another. It is unlikely that novel combinations of these drugs will provide further
improvement in median survival, although there may be advantages to different regimens in terms of
their patient acceptability and toxicity.
Novel agents: There is no evidence that growth factor hibitors affect mesothelioma as beneficial as in
lung cancer. There is active research on immunotherapy (Robinson) and on antiapoptotic agents
(Fennell). It is likely that future studies will focus on the addition of such non-chemotherapy agents to
conventional chemotherapy as adjuvant treatment.
Palliative care: This is often very difficult particularly with the occasional patient who has very
troublesome pain. The pain of mesothelioma is best regarded as neuropathic at the outset in almost all
patients and there is a need for appropriate studies to determine whether triple therapy with novel
opioids and co-analgesics, e.g. Fentanyl, Gabapentin, Benzodiazepines are superior in usual practice to
the traditional opioid and Paracetamol combination. Trials in lung cancer and mesothelioma which have
compared chemotherapy with active supportive care have suggested tantalisingly that pain control may
be better in patients treated with chemotherapy. Whether this is a function of the drugs themselves or
of the use of Dexamethasone as an anti-emetic is not known but if the former, then chemotherapy may
(uniquely) have a role in mesothelioma for this reason.
80% of patients present with a symptomatic pleural effusion. With an increase in the elderly
population, there would be value in a randomised controlled trial of medical or surgical thoracoscopy
versus tube drainage and/or PleurX in patients over, rather than under, 70 years. Likewise there is a
need for a properly powered trial to finally answer the vexed question as to whether prophylactic port-
site radiotherapy is useful or not.
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16B: EGFRopportunities and pitfalls in lung cancer therapy
Dr Ken a'Byrne
St James Hospital, Dublin 8, Ireland
The Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC).
EGFR has become an established target for therapy in NSCLC. EGFR tyrosine kinase inhibitors improve
symptom control, time to tumour progression and overall survival in platinum pretreated patients.
Furthermore, in the chemotherapy na'ive setting, first line treatment of patients with EGFR mutations in
exons 19 and 21, which account for 90% of mutations within the tyrosine kinase domain of the
receptor, results in an "'85% objective response rate and median time to tumour progression (TIP) of
>12 months. A number of questions remain, however, regarding the optimal utilisation of this class of
agent. Can we identify those patients most likely to benefit from therapy as opposed to those for whom
the EGFR TKIs would be of no benefit thus exposing the individual patient to unnecessary side-effects.
Perhaps of greater consequence is whether or not a subgroup of patients exists for whom the EGFR
TKIs are harmful, inducing tumour growth. Are EGFR mutations truly prognostic, predicting outcome
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independent of treatment and/or, apart from objective response, predictive of a better outcome for
patients treated with EGFR TKls as compared to conventional therapies such as chemotherapy and
radiation therapy? Finally will EGFR TKls have a role as maintenance or adjuvant therapy in advanced
and resected disease respectively?
More recently, evidence has emerged that the anti-EGFR monoclonal antibody cetuximab combined
with conventional chemotherapy increases TIP and survival. Can cetuximab be used effectively with all
platinum based chemotherapy regimens? As well as addressing the prognostic and predictive value of
biomarkers in determining outcome to cetuximab combination therapies where do they fit in the the
treatment paradigm for NSCLC? This session will attempt to address some of these issues and provide a
framework for the rationale application of EGFR targeted therapies in the management of NSCLC.
Session 17: Employing molecular biology to understand and treat lung cancer in pre-
clinical models
ProfessorTerence Rabbitts, T. Tanaka
Leeds Institute of MolecularMedicine, Wellcome Trust Brenner Building, St. James's University Hospital,
Leeds, LS9 lTF, UK
RAS family proteins have pivotal roles as molecular switches to transmit a variety of extracellular signals
to the nucleus controlling cell growth, differentiation, migration and survival via the interaction with a
range of effectors molecules. RAS mutations, impairing the GTPase activity and consequently causing
accumulation of active GTP-bound RAS, are found in up to 30% of human cancers, being particularly
prevalent in lung tumours. In addition, secondary RAS-associated signalling aberrations occur by gene
mutation of receptor tyrosine kinases (e.g. EGFR), RAS regulators (e.g. GAP) and RAS effectors (e.g.
PI3Ka, BRAF) in many cancers, suggesting that the overall RAS-signal transduction network is involved
in a high percentage of human cancer. Growing insight in RAS signal transduction reveals that more
than ten proteins with distinct functions (including PI3K, RAF and RALGEF) have been identified as RAS
effectors, directly interacting with RAS to constitute different downstream signalling pathways (e.g.
RAF-MEK-ERK, PI3K-AKT and RALGEF-RAL).
The mutation of the RAS family members, and downstream effectors, are excellent examples of
mutations that can be classified as genotype-specific targets for therapy. Despite many years of
research on RAS mutations and their effects in cancer, attempts to develop drugs directed to RAS have
proven ineffective. We have developed a technique called intracellular antibody capture (lAC) to select
a single variable domain antibody fragment (anti-RAS VH) that specifically binds to activated GTP-
bound RAS and prevents RAS-dependent tumourigenesis in pre-clinical models. The mechanism by
which this anti-RAS VH functions is by inhibition of protein-protein interactions of RAS with its signal
transduction effector proteins.
The crystal structure the RAS-VH complex reveals that the anti-RAS VH binds to the conformationally
variant switch regions of RAS, where its effectors including PI3K, RAF and RALGDS also bind. The VH
inhibits RAS-effector interactions and prevents the constitutive signalling of mutant RAS that causes
tumour growth. Further, the anti-RAS VH inhibits lung tumourigenesis in a RAS-dependent pre-clinical
model in which lung neoplasias arise de novo but crucially the anti-RAS VH alone does not affect
normal lung development or function. Thus anti-RAS VH has potential use in biotherapy as a
macromolecular drug (macrodrug) since as it functions by a different mechanism from anti-RAS
reagents currently in clinical trials. Our findings have implications for use of interfering single domain
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antibody fragments to drug the "undruggable" protein-protein interactions in cancers. Furthermore,
detailed structural and mutational studies of the RAS-VH interface could lead to the prediction of
chemical shapes that may facilitate the synthesis of small molecules with parallel properties to the
interfering macrodrugs.
Session 18: Translating Basic Science into Clinical Practice
Professor David Carbone
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
Mining the proteome for clinically useful lung cancer signatures: Technology and trade-
offs.
Unlike some tumor types, the majority of the common solid tumors appear not to be driven by single
dominant targetable pathways. Instead, diseases such as lung cancer are likely to be much more
complex and heterogeneous, with many distinct and overlapping subsets of tumors within the class,
each of which will demand an in depth analysis to define the optimal therapeutic approach. These
groups are starting to be defined by multiple technologies, and the simplest example is the small subset
of patients with tumors expressing mutant EGFR, who achieve substantial clinical benefit from
minimally toxic targeted therapy. Even for this small subset of patients with mutant epidermal growth
factor receptors (EGFR), multiple resistance mechanisms have emerged requiring different salvage
strategies. DNA sequence analysis will likely yield other small subgroups with direct therapeutic
implications, and expression arrays are beginning to identify others, but analysis of the proteome has
many theoretical advantages, for a complete knowledge of the proteome would encompass all known
mechanisms of functional dysregulation associated with the development of cancer, including DNA
mutations, rearrangements, transcriptional alterations and promoter methylation, but also post-
translational modifications. This depth of information is still far from reality, however, and the true
information content of today's technologies leaves a lot to be desired, but indications of utility are now
being seen.
Using the simple, inexpensive, and rapid technology of matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALDI MS) we studied unfractionated, pretreatment sera to identify
NSCLC patients with improved survival after treatment with the EGFR TKIs gefitinib and erlotinib. Mass
spectra, independently acquired at two institutions, gave highly concordant results, and were used to
generate an algorithm predictive of time to progression and survival. This prediction algorithm was then
validated in a blinded manner in two independent cohorts of NSCLC patients treated with EGFR TKIs.
This classification algorithm did not predict outcome in three independent cohorts of patients who did
not receive treatment with EGFR TKIs. Thus, if upheld in prospective clinical trials, this analysis of pre-
treatment peripheral blood might be useful in selecting therapy for advanced non-small cell lung cancer
patients. We are currently in the process of testing this signature in sample sets from past randomized
clinical trials, and a prospective trial is underway.
We have also used this technology to develop signatures predicted of response to chemotherapy in
lung cancer cell lines and applied the resulting signatures to tumors resected with curative intent. This
signature accurately classified survival for patients who received adjuvant chemotherapy, and not for
those who did not, suggesting that it might be predictive of benefit from adjuvant chemotherapy, and
not merely prognostic.
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New technologies, such as shotgun proteomics, that give far more detailed information have also been
far more cumbersome and less reproducible. However, we are now able to achieve a depth of
information comparable to expression microarray analysis using shotgun proteomics of tumor and
normal samples, with improving reproducibility. This is allowing for the more practical analysis of single
samples, and definition of activated pathways in tumor cells in real-time. Direct quantitation of specific
peptides of interest can also be achieved. It is likely that as the technology improves, proteomic
signatures of cancer will be a significant source of information enabling the development of clinically
useful individualized of risk assessments and therapeutic decision-making.
Professor Michael seckl
Division of Medicine, Faculty of Medicine, Imperial College, London, UK
Mining the proteome for clinically useful lung cancer signatures: Technology and trade-
offs.
Unlike some tumor types, the majority of the common solid tumors appear not to be driven by single
dominant targetable pathways. Instead, diseases such as lung cancer are likely to be much more
complex and heterogeneous, with many distinct and overlapping subsets of tumors within the class,
each of which will demand an in depth analysis to define the optimal therapeutic approach. These
groups are starting to be defined by multiple technologies, and the simplest example is the small subset
of patients with tumors expressing mutant EGFR, who achieve substantial clinical benefit from
minimally toxic targeted therapy. Even for this small subset of patients with mutant epidermal growth
factor receptors (EGFR), multiple resistance mechanisms have emerged requiring different salvage
strategies. DNA sequence analysis will likely yield other small subgroups with direct therapeutic
implications, and expression arrays are beginning to identify others, but analysis of the proteome has
many theoretical advantages, for a complete knowledge of the proteome would encompass all known
mechanisms of functional dysregulation associated with the development of cancer, including DNA
mutations, rearrangements, transcriptional alterations and promoter methylation, but also post-
translational modifications. This depth of information is still far from reality, however, and the true
information content of today's technologies leaves a lot to be desired, but indications of utility are now
being seen.
Using the simple, inexpensive, and rapid technology of matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry (MALOI MS) we studied unfractionated, pretreatment sera to identify
NSCLC patients with improved survival after treatment with the EGFR TKIs gefitinib and erlotinib. Mass
spectra, independently acquired at two institutions, gave highly concordant results, and were used to
generate an algorithm predictive of time to progression and survival. This prediction algorithm was then
validated in a blinded manner in two independent cohorts of NSCLC patients treated with EGFR TKIs.
This classification algorithm did not predict outcome in three independent cohorts of patients who did
not receive treatment with EGFR TKIs. Thus, if upheld in prospective clinical trials, this analysis of pre-
treatment peripheral blood might be useful in selecting therapy for advanced non-small cell lung cancer
patients. We are currently in the process of testing this signature in sample sets from past randomized
clinical trials, and a prospective trial is underway.
We have also used this technology to develop signatures predicted of response to chemotherapy in
lung cancer cell lines and applied the resulting signatures to tumors resected with curative intent. This
signature accurately classified survival for patients who received adjuvant chemotherapy, and not for
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those who did not, suggesting that it might be predictive of benefit from adjuvant chemotherapy, and
not merely prognostic.
New technologies, such as shotgun proteomics, that give far more detailed information have also been
far more cumbersome and less reproducible. However, we are now able to achieve a depth of
information comparable to expression microarray analysis using shotgun proteomics of tumor and
normal samples, with improving reproducibility. This is allowing for the more practical analysis of single
samples, and definition of activated pathways in tumor cells in real-time. Direct quantitation of specific
peptides of interest can also be achieved. It is likely that as the technology improves, proteomic
signatures of cancer will be a significant source of information enabling the development of clinically
useful individualized of risk assessments and therapeutic decision-making.
Dr Fred Hirsch
Department of Pathology, University of Colorado, Health Science Center, Denver, USA
Increased EGFRgene copy number by fish predicts sensitivity to EGFR-Inhibitors in NSCLC.
EGFR Tyrosine Kinase Inhibitors (TKIs) are effective in a subgroup of patients with NSCLC. About 10 %
of the patients will have objective response and additional 30-40% will have stable disease. Thus,
about 50% will have disease control and clinical benefit. The challenge is how to select the patients
who will have clinical benefit.
At the University of Colorado Cancer Center a strong emphasis is put into preclinical studies. We tested
a large number of NSCLC cell lines for sensitivity to gefitinib based on MTT assay, and according to IC-
50 values they were grouped into sensitive (Ie 50< 1.0_M) or resistant (Ie 50> lO_M). Based on the
FISH assay we developed an EGFR gene copy number classification and studied the cell lines for EGFR
gene copy number. A strikingly good concordance was observed between in vitro sensitivity and
increased gene copy number. This finding was then tested in several clinical study cohorts, including
the two prospective placebo- controlled randomized trials of EGFR TKIs (BR-21 for erlotinib and ISEL
for gefitinib). Both studies verified a strong correlation between sensitivity/outcome to EGFR TKIs and
increased gene copy number. The EGFR FISH assay as a predictive marker for EGFR TKIs is currently
prospective validated in a US NCI/Intergroup study including 1.200 patients. Most recently also a strong
correlation between increased EGFR gene copy number by FISH and outcome to the monoclonal
antibody cetuximab was observed in a study by the Southwest Oncology Group (0342).
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Department of Surgery, University of Michigan, USA
Multi-Center Validation Study of Lung Adenocarcinoma Based on Gene Expression.
Gene expression analyses utilizing microarrays can recapitulate the known histological heterogeneity of
lung cancer as well as identify profiles for patients with different survival among early stage lung
cancer.
The general applicability of most classifiers unfortunately has not been easy to establish as the
numbers of tumor samples tested in various studies have often been small or without uniform criteria
for sample inclusion, annotation, sample processing, and data analyses. To address these issues as well
as generate a large microarray database of lung cancer samples, we have formed a research
consortium and conducted a large retrospective, multi-site, blinded study of lung adenocarcinomas, a
diverse subtype of non-small cell lung cancers that are increasing in incidence and for which additional
information regarding specific tumor subgroups is lacking. We have previously established the
consortium's ability to perform and analyze samples with a multi-site based study (Dobbin et ai, Clin.
Cancer Res., 2005; PMID: 15701842) that involve a pre-defined analysis procedure and following a
common protocol. The present study included a blinded validation step to characterize the performance
of several newly-developed prognostic models using Affymetrix U133A microarrays to assay gene
expression among a total of 442 lung adenocarcinomas.
Patient samples along with all relevant clinical, outcome data, frozen section and permanent specimen
pathology were collected by investigators at four institutions using data from six lung cancer treatment
sites with a priori defined inclusion criteria. Four individual hypotheses were examined: 1. Gene
expression alone can predict outcomes for all samples; 2. Gene expression and basic clinical covariates
(stage, age, gender) can predict outcomes for all samples; 3. Gene expression alone can predict
outcomes for stage 1 samples; and 4. Gene expression and basic clinical covariates can predict
outcomes for stage 1 samples. Gene expression-based prediction is only relevant in practice if it
provides additional information beyond known clinical parameters. A major aspect of our study was the
defined protocol for the data collection, data analysis, and performance evaluation during each portion
of the study. Two hundred fifty eight (258) samples from two of the laboratories were used to train 8
prognostic models, with the remaining two independent data sets (104 and 82 samples, respectively)
held blinded by a third party.
The 8 models were then applied to the blinded data, and were evaluated separately using the sets of
patient samples appropriate for each hypothesis (either all samples or all stage 1 samples). In addition,
several methods based on published approaches and the base line clinical variable-only approach, were
trained and used for comparison. For each of the four hypotheses, several of the models produced risk
scores and ROC curves that substantially correlated with actual patient outcome and most performed
better with clinical data, supporting the combined use of clinical and molecular information when
building prognostic models for early stage lung cancer.
The results from this study provide not only valid assessment of outcome prediction in the multi-
institutional setting but also a rich dataset for future analysis and provide an example of how large
datasets can be generated and tested by cooperation and pooling of resources among many
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investigators. This study demonstrates that several gene expression signatures for clinical outcomes in
lung adenocarcinomas have prognostic value even with the inter-laboratory variation and patient
heterogeneity expected in multi-institutional studies. It also demonstrates the challenges of building
predictive models for lung cancer using gene expression measurements, and confirms that models can
be built that predict patient outcomes in independent datasets.
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